Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 9.554
Filtrar
1.
Rev Med Suisse ; 16(676-7): 78-80, 2020 Jan 15.
Artigo em Francês | MEDLINE | ID: mdl-31961090

RESUMO

Except for bisphosphonates, the duration of anti-osteoporotic treatment is not limited to 3 to 5 years. T-score between - 2.0 and - 1.5 DS might be the BMD target to reach before considering discontinuing anti-osteoporosis treatment. A rebound of bone remodeling can occur in some patients despite receiving zoledronate after denosumab discontinuation, and the monitoring of CTX is required. There is no benefit of vitamin D supplementation on musculoskeletal health in the general population, but vitamin D remains indicated in patients with vitamin D deficiency or receiving osteoporosis treatment. A sequential treatment with romosozumab during one year, a bone anabolic anti-sclerostin antibody, followed by two years of denosumab, decreases vertebral and non-vertebral fractures with rapid and substantial BMD gains after 3 years.


Assuntos
Conservadores da Densidade Óssea , Remodelação Óssea , Osteoporose Pós-Menopausa , Osteoporose , Densidade Óssea , Conservadores da Densidade Óssea/uso terapêutico , Osso e Ossos , Denosumab , Difosfonatos , Humanos , Osteoporose/tratamento farmacológico , Osteoporose Pós-Menopausa/tratamento farmacológico
2.
Medicine (Baltimore) ; 99(2): e18698, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31914073

RESUMO

INTRODUCTION: Alendronate sodium is used to reduce the risk of bone fracture in aged osteoporosis patients. However, its side effects should be recognized, especially for those aged patients with one or more basic cardiovascular diseases. PATIENT CONCERNS: A 90-year-old and a 75-year-old male patient were admitted to our department. These 2 patients were examined by dual energy X-ray absorptiometry (DXA). DIAGNOSIS: Both patients were diagnosed with osteoporosis, they also had history of atrial fibrillation (AF) and had long term use of warfarin. INTERVENTIONS: Alendronate sodium was prescribed to the two patients at 70 mg once a week. OUTCOMES: The 2 patients had experienced dramatic increase of international normalized ratio (INR) to 4.69∼4.86 within 24 hours and gradual decrease in the next 5 days. Both patients experienced spontaneous ecchymoses and petechiae in the skin at the first 72 hours. CONCLUSION: Alendronate sodium can transiently increase the INR over 50%, induce spontaneous ecchymoses and petechiae in the skin of aged male osteoporosis patients with AF who took warfarin. Clinicians should pay enough attention when using alendronate sodium on these kinds of patients and be aware of the consequent potential bleeding risk.


Assuntos
Alendronato/efeitos adversos , Anticoagulantes/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Conservadores da Densidade Óssea/efeitos adversos , Osteoporose/tratamento farmacológico , Varfarina/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Alendronato/uso terapêutico , Conservadores da Densidade Óssea/uso terapêutico , Sinergismo Farmacológico , Humanos , Coeficiente Internacional Normatizado , Masculino
3.
Internist (Berl) ; 61(1): 51-63, 2020 Jan.
Artigo em Alemão | MEDLINE | ID: mdl-31848647

RESUMO

Over 6 million people in Germany suffer from osteoporosis; approximately half of all women over 70 years old and approximately 1 in 5 men over 70 years old are affected. The most relevant clinical consequences of the disease are fractures leading to a clear impairment in the quality of life. Furthermore, following an osteoporotic fracture especially of the hip or vertebra there is increased mortality. Despite higher individual and socioeconomic relevance, too few patients with osteoporosis still receive adequate treatment. Based on the current guidelines of the governing body for osteology (DVO) the indications for specific medicinal treatment can be determined. Furthermore, the selection of the suitable osteoporosis medication can be carried out by considering several factors, including individual ones.


Assuntos
Conservadores da Densidade Óssea/uso terapêutico , Osteoporose/diagnóstico , Osteoporose/tratamento farmacológico , Fraturas por Osteoporose/diagnóstico , Fraturas por Osteoporose/tratamento farmacológico , Idoso , Feminino , Alemanha , Humanos , Masculino , Osteoporose/psicologia , Fraturas por Osteoporose/psicologia , Guias de Prática Clínica como Assunto , Qualidade de Vida
4.
Zhongguo Zhong Yao Za Zhi ; 44(18): 4048-4052, 2019 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-31872744

RESUMO

Osteoporosis is a systematic bone disease,characterized by deterioration in bone mass or micro-architecture,and increasing risk of fragility and fractures. With the development of aging problems,osteoporosis has been a global health problem. At present,due to the undesirable side effects of synthetic osteoporosis inhibitors,more efforts are made in treatment of osteoporosis by traditional Chinese medicine and its prescriptions. Epimedii Folium,one of the most common herbs for osteoporosis,has attracted great attentions worldwide.In this study,network pharmacology was employed to analyze the active components and potential molecular mechanism of Epimedii Folium on osteoporosis. Component-target network analysis showed that those with higher molecular network degree were flavonoids,with estrogen-like activity,antioxidation and free radical-scavenging activities,playing certain roles in preventing and treating osteoporosis. On the other hand,the targets with high degree were mostly related with sex hormone,osteoclast differentiation,bone matrix degradation,and reactive oxygen species in drug-target network. Multiple components of Epimedii Folium could be interacted with these targets. This study shows that Epimedium could prevent and treat osteoporosis through multiple active ingredients acting on multiple targets.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Epimedium/química , Osteoporose/tratamento farmacológico , Humanos , Medicina Tradicional Chinesa , Folhas de Planta/química , Plantas Medicinais/química
5.
Adv Exp Med Biol ; 1182: 263-269, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31777023

RESUMO

The anti-osteoporosis effect of Ganoderma lucidum (G. lucidum, Lingzhi) is closely associated with inhibition of osteoclastogenesis in the charge of osteoclasts. This article reviewed the anti-osteoporosis effect of Ganoderma and its active components, including a kind of triterpenoids, a polysaccharide and a protein named Ling Zhi-8 (LZ-8). Triterpenoids are a kind of active compounds as candidates for the treatment of osteoporosis. Among these, ganoderic acids are currently considered as the most important and potential components, and their structure-activity relationship highlights the essential group to hamper osteoclast differentiation. The data confirmed that the active compounds isolated from triterpenoids and meroterpenoids could suppress bone resorption of osteoclast via RANKL/RANK pathway and/or its downstream signaling transduction related to ERK, JNK and p38 MAPKs, contributing to inhibition of the level of c-Fos and NFATc1, two key target genes of osteoclast for osteoclastogenesis. However, the comprehensive mechanism remains to be elucidated in the future.


Assuntos
Produtos Biológicos/farmacologia , Osteogênese/efeitos dos fármacos , Osteoporose/tratamento farmacológico , Reishi/química , Diferenciação Celular , Humanos , Osteoclastos/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos
7.
Presse Med ; 48(11 Pt 1): 1261-1264, 2019 Nov.
Artigo em Francês | MEDLINE | ID: mdl-31735525

RESUMO

The impact of antihypertensive drugs on blood pressure does not differ according to the sex. There are women-specific conditions or medical conditions encountered more frequently among womens that guide the selection of therapy such as a desire to become pregnant, a pregnancy, a polycystic ovarian syndrome, breast cancer, osteoporosis or migraine.


Assuntos
Anti-Hipertensivos/uso terapêutico , Hipertensão/tratamento farmacológico , Fatores Etários , Anti-Hipertensivos/efeitos adversos , Pressão Sanguínea/efeitos dos fármacos , Neoplasias da Mama/induzido quimicamente , Feminino , Humanos , Transtornos de Enxaqueca , Osteoporose/complicações , Osteoporose/tratamento farmacológico , Síndrome do Ovário Policístico/tratamento farmacológico , Gravidez , Fatores Sexuais , Espironolactona/efeitos adversos
8.
Sichuan Da Xue Xue Bao Yi Xue Ban ; 50(5): 679-683, 2019 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-31762237

RESUMO

OBJECTIVE: To test the effects of Guben Zenggu Decoction on bone metabolism and bone microstructure in ovariectomized rats for the purpose of preventing and treating postmenopausal osteoporosis. METHODS: Osteoporosis rat models were established by ovariectomy. The model rats were randomly divided into control, estradiol valerate treatment, and Guben Zenggu Decoction treatment groups with high, medium and low dosages. After 12 weeks of treatments, 10 rats from each group were randomly selected for cardiac blood sampling after abdominal anesthesia. The serum levels of estradiol (E2), osteocalcin (BGP), carboxyterminal of type Ⅰ procollagen (PICP), collagen type Ⅰ pyridine crosslinking peptide (ICTP) and acid tartaric acid phosphatase-5b (TRAP-5b) were determined by ELISA. Bone histomorphometric analysis was performed on the right femoral specimen of rats using micro-CT imaging. RESULTS: The models rats had lower levels of E2, bone alkaline phosphatase (BALP) and relative bone volume fraction (BV/TV), trabecular thickness (Tb.Th), number of trabeculae (Tb.N) and connectivity density (Conn.D), and higher levels of BGP, ICTP, PICP, TRAP-5b and degree of trabecular separation (Tb.Sp), structural model index (SMI) than their normal counterparts (P < 0.05). Estradiol valerate and Guben Zenggu Decoction treatments increased the levels of E2, BALP, BV/TV, Tb.Th, Tb.N, and Conn.D significantly (P < 0.05). Higher doses of Guben Zenggu Decoction resulted in higher changes (P < 0.05). CONCLUSION: Guben Zenggu Decoction can improve bone metabolism and bone micro-structure in ovariectomized rats, thus playing a preventive and therapeutic role in postmenopausal osteoporosis.


Assuntos
Densidade Óssea/efeitos dos fármacos , Osso e Ossos/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Osteoporose/tratamento farmacológico , Animais , Osso e Ossos/efeitos dos fármacos , Feminino , Ovariectomia , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Microtomografia por Raio-X
10.
Z Rheumatol ; 78(10): 904-909, 2019 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-31654138

RESUMO

The occurrence of multiple vertebral fractures after discontinuation of denosumab in the treatment of osteoporosis has reopened the debate on the optimal treatment duration and drug holidays.In principle, there is a difference in this regard between the discontinuation of medications such as bisphosphonates and substances without bone retention such as selective estrogen receptor modulators (SERMs), denosumab or teriparatide. Even after the end of application bisphosphonates have a very long half-life in the bones. After cessation of drug intake there is a slow, slight increase of bone turnover markers. Even after cessation of the SERM raloxifene, a decline in bone density can be observed, as with the termination of teriparatide. In contrast to these osteoporosis medications, after cessation of denosumab, a steep and rapid increase in markers of bone resorption above baseline levels ("rebound") and a reduction in bone mineral density to initial values can be observed.Osteoporosis is a disease that carries an increased risk of fracture, which is reduced for the duration of osteoporosis treatment. In certain situations, the fracture risk is only temporarily raised. In these situations, cessation of the osteoporosis treatment is possible. Beyond these special clinical situations, however, osteoporosis needs to be addressed as a chronic disease with a permanently increased fracture risk and the indication for therapy should be evaluated according to the extent of the risk of fracture.What happens after discontinuation of anti-osteoporosis drugs? The various effects on bone turnover markers, bone mineral density and fracture incidence of the individual drug groups are presented in detail, as are the resulting recommendations of the task forces of the American Society of Bone and Mineral Research (ASBMR) and the European Calcified Tissue Society (ECTS).


Assuntos
Conservadores da Densidade Óssea , Osteoporose , Densidade Óssea , Conservadores da Densidade Óssea/uso terapêutico , Denosumab , Difosfonatos , Humanos , Osteoporose/tratamento farmacológico
12.
Life Sci ; 237: 116890, 2019 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-31606379

RESUMO

AIMS: Telmisartan (TEL), an angiotensin II type I receptor blocker and PPARγ partial agonist, has been used for to treat hypertension. It is known that PPARγ activation induces bone loss. Therefore, we evaluate the effects of telmisartan on PPARγ protein expression, biomechanics, density and bone microarchitecture of femurs and lumbar vertebrae in SHR ovariectomized animals, a model of hypertension in which preexisting bone impairment has been demonstrated. MAIN METHODS: SHR females (3 months old) were distributed into four groups: sham (S), sham + TEL (ST), OVX (C) and OVX + TEL (CT). TEL (5 mg/kg/day) or vehicle were administered according to the groups. After the protocol, blood pressure was measured and density, microarchitecture and biomechanics of bone were analyzed. Western blotting analysis was performed to evaluate PPARγ protein expression in the bones. KEY FINDINGS: Castration induced a deleterious effect on mineral density and trabecular parameters, with telmisartan enhancing such effects. Telmisartan increased PPARγ levels, which were at their highest when the treatment was combined with castration. As to biomechanical properties, telmisartan reduced the stiffness in the castration group (CT vs. S or C group), as well as resilience and failure load in ST group (vs. all others groups). SIGNIFICANCE: These results demonstrated that telmisartan compromised bone density and microarchitecture in animals that shows preexisting osteoporotic bone disorders, probably via mechanisms associated with increased PPARγ. If this translates to humans, a need for greater caution in the use of telmisartan by patients that have preexisting bone problems, as in the postmenopausal period, may be in order.


Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Doenças Ósseas/tratamento farmacológico , Osso Esponjoso/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Osteoporose/tratamento farmacológico , PPAR gama/metabolismo , Telmisartan/farmacologia , Animais , Densidade Óssea/efeitos dos fármacos , Doenças Ósseas/metabolismo , Doenças Ósseas/fisiopatologia , Osso Esponjoso/diagnóstico por imagem , Osso Esponjoso/patologia , Feminino , Osteoporose/metabolismo , Osteoporose/fisiopatologia , PPAR gama/genética , Ratos , Ratos Endogâmicos SHR , Tomografia Computadorizada por Raios X
13.
Int J Nanomedicine ; 14: 7839-7849, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31576127

RESUMO

Background: Nobiletin (NOB), a polymethoxy flavonoid, possesses anti-cancer and anti-inflammatory activities, has been reported that it played role in anti-osteoporosis treatment. However, previous research did not focus on practical use due to lack of hydrophilicity and cytotoxicity at high concentrations. The aim of this study was to develop a therapeutic formulation for osteoporosis based on the utilization of NOB. Methods: In this study, NOB-loaded poly(ethylene glycol)-block-poly(e-caprolactone) (NOB-PEG-PCL) was prepared by dialysis method. The effects on osteoclasts and anti-osteoporosis functions were investigated in a RANKL-induced cell model and ovariectomized (OVX) mice. Results: Dynamic light scattering and transmission electron microscopy examination results revealed that the NOB-PEG-PCL had a round shape, with a mean diameter around 124 nm. The encapsulation efficiency and drug loading were 76.34±3.25% and 7.60±0.48%, respectively. The in vitro release of NOB from NOB-PEG-PCL showed a remarkably sustained releasing characteristic and could be retained at least 48 hrs in pH 7.4 PBS. Anti-osteoclasts effects demonstrated that the NOB-PEG-PCL significantly inhibited the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells stimulated by RANKL. Furthermore, the NOB-PEG-PCL did not produce cytotoxicity on bone marrow-derived macrophages (BMMs). The mRNA expressions of genetic markers of osteoclasts including TRAP and cathepsin K were significantly decreased in the presence of NOB-PEG-PCL. In addition, the NOB-PEG-PCL inhibited OC differentiation of BMMs through RANKL-induced MAPK signal pathway. After administration of the NOB-PEG-PCL, NOB-PEG-PCL prevented bone loss and improved bone density in OVX mice. These findings suggest that NOB-PEG-PCL might have great potential in the treatment of osteoporosis. Conclusion: The results suggested that NOB-PEG-PCL micelles could effectively prevent NOB fast release from micelles and extend circulation time. The NOB-PEG-PCL delivery system may be a promising way to prevent and treat osteoporosis.


Assuntos
Reabsorção Óssea/tratamento farmacológico , Reabsorção Óssea/etiologia , Flavonas/uso terapêutico , Micelas , Osteoclastos/patologia , Osteogênese , Ovariectomia/efeitos adversos , Animais , Morte Celular/efeitos dos fármacos , Citocinas/metabolismo , Liberação Controlada de Fármacos , Feminino , Flavonas/química , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Camundongos Endogâmicos C57BL , Osteoclastos/efeitos dos fármacos , Osteogênese/efeitos dos fármacos , Osteoporose/tratamento farmacológico , Poliésteres/química , Polietilenoglicóis/química , Transdução de Sinais/efeitos dos fármacos
14.
Bone Joint J ; 101-B(10): 1285-1291, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31564154

RESUMO

AIMS: Currently, periprosthetic fractures are excluded from the American Society for Bone and Mineral Research (ASBMR) definition of atypical femoral fracture (AFFs). This study aims to report on a series of periprosthetic femoral fractures (PFFs) that otherwise meet the criteria for AFFs. Secondary aims were to identify predictors of periprosthetic atypical femoral fractures (PAFFs) and quantify the complications of treatment. PATIENTS AND METHODS: This was a retrospective case control study of consecutive patients with periprosthetic femoral fractures between 2007 and 2017. Two observers identified 16 PAFF cases (mean age 73.9 years (44 to 88), 14 female patients) and 17 typical periprosthetic fractures in patients on bisphosphonate therapy as controls (mean age 80.7 years (60 to 86, 13 female patients). Univariate and multivariate analysis was performed to identify predictors of PAFF. Management and complications were recorded. RESULTS: Interobserver agreement for the PAFF classification was excellent (kappa = 0.944; p < 0.001). On univariate analysis compared with controls, patients with PAFFs had higher mean body mass indices (28.6 kg/m2 (sd 8.9) vs 21.5 kg/m2 (sd 3.3); p = 0.009), longer durations of bisphosphonate therapy (median 5.5 years (IQR 3.2 to 10.6) vs 2.4 years (IQR 1.0 to 6.4); p = 0.04), and were less likely to be on alendronate (50% vs 94%; p = 0.02) with an indication of secondary osteoporosis (19% vs 0%; p = 0.049). Duration of bisphosphonate therapy was an independent predictor of PAFF on multivariate analysis (R2 = 0.733; p = 0.05). Following primary fracture management, complication rates were higher in PAFFs (9/16, 56%) than controls (5/17, 29%; p = 0.178) with a relative risk of any complication following PAFF of 1.71 (95% confidence interval (CI) 0.77 to 3.8) and of reoperation 2.56 (95% CI 1.3 to 5.2). CONCLUSION: AFFs do occur in association with prostheses. Longer duration of bisphosphonate therapy is an independent predictor of PAFF. Complication rates are higher following PAFFs compared with typical PFFs, particularly of reoperation and infection. Cite this article: Bone Joint J 2019;101-B:1285-1291.


Assuntos
Artroplastia de Quadril/efeitos adversos , Difosfonatos/efeitos adversos , Osteoporose/tratamento farmacológico , Fraturas Periprotéticas/induzido quimicamente , Fraturas Periprotéticas/cirurgia , Idoso , Idoso de 80 Anos ou mais , Artroplastia de Quadril/métodos , Estudos de Casos e Controles , Intervalos de Confiança , Difosfonatos/uso terapêutico , Relação Dose-Resposta a Droga , Feminino , Fraturas do Fêmur/induzido quimicamente , Fraturas do Fêmur/cirurgia , Seguimentos , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Variações Dependentes do Observador , Osteoporose/complicações , Fraturas Periprotéticas/diagnóstico por imagem , Estudos Retrospectivos , Medição de Risco , Fatores de Tempo , Estados Unidos
15.
Wiad Lek ; 72(9 cz 1): 1641-1645, 2019.
Artigo em Polonês | MEDLINE | ID: mdl-31586976

RESUMO

Basing on European, American and Polish recommendation reviewed are strategy of treatment of osteoporosis. In Poland, rules of reimbursement reinforced general use of antiresorbtive drugs (bisphosponates, demosumab) in the treatment of osteoporosis. For effective therapy the key points are keeping the patient in the treatment and treatment monitoring with potential use of densitometry and bone markers.


Assuntos
Conservadores da Densidade Óssea/uso terapêutico , Osteoporose/tratamento farmacológico , Quimioterapia Combinada , Humanos , Polônia
16.
Zhonghua Kou Qiang Yi Xue Za Zhi ; 54(9): 632-638, 2019 Sep 09.
Artigo em Chinês | MEDLINE | ID: mdl-31550788

RESUMO

Objective: To investigate the regulation of curculigoside on osteogenic differentiation of MG63 and the protective effect on osteoporosis model mice. Methods: The effects of curculigoside on the survival rate of dexamethasone or H(2)O(2) treated MG63 were detected by methyl thiazolyl tetrazolium (MTT). The specimens were divided into six groups: blank control group, blank administration group, model group (dexamethasone or H(2)O(2) treatment group), low dose group (dexamethasone or H(2)O(2)+1.0 µmol/L curculigoside), medium dose group (dexamethasone or H(2)O(2)+2.5 µmol/L curculigoside) and high dose group (dexamethasone or H(2)O(2)+5.0 µmol/L curculigoside), the sample size of each group was 10. Western blotting was used to detect the expression of osteogenic differentiation-related proteins [type Ⅰ collagen, integrin ß1, osteoblast-specific transcription factor (Osterix), osteocalcin and osteopontin] in MG63 cells after 1, 7 and 14 days incubated with 0, 1.0, 2.5 and 5.0 µmol/L of curculigoside. The sample size for each group at each time point was six. The experimental mice were divided into 4 groups: blank group, model group (dexamethasone treatment group), curculigoside low-dose group (dexamethasone+5 mg/kg curculigoside) and high-dose group (dexamethasone+45 mg/kg curculigoside), twenty each. After treatment, the tibia of the mice in each group were subjected to sacral HE staining. The number of osteoclasts was counted, and the levels of oxidative related factors in serum were determined by enzyme-linked immunosorbent assay (ELISA). Results: The MTT results showed that compared with the blank control group [(100±3.7)%], the cell survival rate decreased to (44.1±5.7)% after treatment with dexamethasone, and the survival rate increased to (79.7±3.8)% after treatment with 5.0 µmol/L of curculigoside. The cell survival rate decreased to (59.1±4.7)% after H(2)O(2) treatment, and the survival rate increased to (80.8±3.5)% after treatment with 2.5 µmol/L of curculigoside. The results of Western blotting showed that the expression of type Ⅰ collagen and integrin ß1 in MG63 cells was significantly increased after 1.0, 2.5 and 5.0 µmol/L of curculigoside for 1, 7 and 14 days compared with 0 µmol/L of curculigo side for the same period. After increasing (P<0.05), the expression of Osterix and osteocalcin was significantly increased after 1 day of incubation (P<0.05). However, compared with 0 µmol/L curculigoside treatment, the expression of osteopontin in MG63 cells was not significantly different after incubation with 1.0, 2.5, 5.0 µmol/L of curculigoside for 7 and 14 days (P>0.05). Compared with the blank group, the number of tibia osteoclasts in the osteoporosis model group increased. In the low-dose and high-dose groups of curculigoside, the tibia cortex was more continuous and the number of osteoclasts decreased. Compared with the blank group, the activity of oxygen in the osteoporosis model group was significantly increased (P<0.05), and superoxide dimutase and catalase were significantly decreased (P<0.05). Conclusions: Curculigoside promotes the differentiation of MG63 cells by increasing the expression of osteoblast differentiation-related proteins, and has a certain therapeutic effect on dexamethasone-induced osteoporosis mice.


Assuntos
Benzoatos , Glucosídeos , Osteogênese , Osteoporose , Animais , Benzoatos/farmacologia , Modelos Animais de Doenças , Glucosídeos/farmacologia , Peróxido de Hidrogênio , Camundongos , Osteogênese/efeitos dos fármacos , Osteoporose/tratamento farmacológico
18.
Praxis (Bern 1994) ; 108(12): 799-806, 2019 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-31530124

RESUMO

From Axial Spondyloarthritis to Osteoporosis - Spectrum of Skeletal Involvement in Inflammatory Bowel Diseases Abstract. Inflammatory bowel diseases (IBD) are frequently accompanied by non-inflammatory joint pain and inflammatory spondyloarthritides. Spondyloarthritides can restrict joint function and typically manifest with inflammatory back pain with nightly pain and morning stiffness that improves upon exercising. In other patients, small or large peripheral joints are predominantly involved. Treatment comprises pain medication including COX-II selective non-steroidal anti-inflammatory drugs (NSAID), since non-selective NSAID can aggravate IBD. For axial manifestations, physiotherapy and tumor necrosis factor (TNF) inhibitors are effective, while for peripheral manifestations steroid injections, sulfasalazine and TNF inhibitors are useful. Osteopenia and osteoporosis may result from inflammation, malabsorption and/or steroids. Long-lasting disease activity or steroid treatment should prompt osteoporosis screening. Adequate calcium and vitamin D intake must be ensured and treatment with bisphosphonates evaluated.


Assuntos
Doenças Inflamatórias Intestinais , Osteoporose , Espondilartrite , Anti-Inflamatórios não Esteroides/uso terapêutico , Humanos , Doenças Inflamatórias Intestinais/complicações , Doenças Inflamatórias Intestinais/tratamento farmacológico , Osteoporose/complicações , Osteoporose/tratamento farmacológico , Espondilartrite/complicações , Espondilartrite/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores
19.
Shanghai Kou Qiang Yi Xue ; 28(3): 241-245, 2019 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-31489409

RESUMO

PURPOSE: To study the effects of curcumin on EZH2 mRNA expression in the mandible and femur of ovariectomized osteoporosis rats,and to investigate its protective effect and mechanism. METHODS: Thirty female 6-month old SD rats were randomly divided into sham group,OVX group and experimental group. The rats in the experimental groups were given curcumin (110 mg/kg) by intragastric administration after ovariectomy, while rats in the sham group and OVX group were given the same dosage of carboxymethylcellulose sodium solution, once a day for 12 weeks. All rats were sacrificed after the last intragastric administration. The serum samples were collected for detemination of biochemistrical parameters. Micro-CT was used for bone parameters and the morphology of the trabecular bone of the left mandibles and femurs. The expression level of EZH2mRNA in right mandible and femurs tissue was detected by reverse transcription polymerase chain reaction (RT-PCR). SPSS22.0 software package was used for statistical analysis. RESULTS: The expression of EZH2mRNA in the OVX group was significantly higher than the sham group (P<0.05). Compared with the OVX group,curcumin increased BMD and improved bone microstructure, decreased serum contents of alkaline phosphatase,and down-regulated the expression levels of EZH2mRNA in bone tissues of rats with osteoporosis (P<0.05). CONCLUSIONS: Curcumin can effectively prevent the lose of bone volume of ovariectomized rats, and repaire bone microstructure. Its mechanism is related with down -regulation of EZH2mRNA.


Assuntos
Curcumina , Proteína Potenciadora do Homólogo 2 de Zeste , Inibidores Enzimáticos , Osteoporose , Animais , Densidade Óssea , Curcumina/farmacologia , Proteína Potenciadora do Homólogo 2 de Zeste/metabolismo , Inibidores Enzimáticos/farmacologia , Feminino , Humanos , Mandíbula , Osteoporose/tratamento farmacológico , Ovariectomia , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley
20.
Acta Ortop Mex ; 33(1): 39-41, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31480125

RESUMO

INTRODUCTION: Bisphosphonates have been the gold standard in the management of osteoporosis. Its antiresorptive effect has reduced the incidence of fractures due to bone fragility, as well as its impact on public health. We present the clinical case of a patient in prolonged treatment with bisphosphonates and atypical bilateral femur fracture. CASE REPORT: A 65-year-old female who presented a fall from her own height, on treatment with risedronate for seven years, and a history of systemic arterial hypertension and hypercholesterolemia, both with medical treatment. Diagnosed with bilateral atypical femoral fracture, treated with closed reduction internal fixation (CRIF) with intramedullary nailing, application of calcium citrate and teriparatide. DISCUSSION: Multiple studies indicate that the benefit of using bisphosphonates for osteoporosis is higher than the risk of presenting atypical fractures.


Assuntos
Conservadores da Densidade Óssea , Fraturas do Fêmur , Osteoporose , Idoso , Conservadores da Densidade Óssea/efeitos adversos , Difosfonatos , Feminino , Fraturas do Fêmur/etiologia , Humanos , Osteoporose/tratamento farmacológico , Teriparatida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA